Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

被引：21

作者：

Marcellino, Daniel ^{[1
]}

Lindqvist, Eva ^{[1
]}

Schneider, Marion ^{[2
]}

Mueller, Christa E. ^{[2
]}

Fuxe, Kjell ^{[1
]}

Olson, Lars ^{[1
]}

Galter, Dagmar ^{[1
]}

机构：

[1] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden

[2] Univ Bonn, PharmaCtr Bonn, Inst Pharmaceut, D-53121 Bonn, Germany

来源：

NEUROBIOLOGY OF DISEASE | 2010年 / 40卷 / 02期

基金：

瑞典研究理事会;

关键词：

Striatum; Parkinson's disease; L-DOPA; Dopamine; Spontaneous locomotion; Drug-induced locomotor activity; HPLC; Western blot; Mass spectrometry; ADENOSINE RECEPTOR ANTAGONISTS; DISEASE; CAFFEINE; ISTRADEFYLLINE; DOPA; NEUROPROTECTION; PROGRESSION; BLOCKADE; MODELS; TRIAL;

D O I：

10.1016/j.nbd.2010.07.008

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Adenosine A(2A) receptor (A(2A)R) antagonists are being investigated as promising treatment strategy for Parkinson's disease (PD). To test whether A(2A)R antagonists are beneficial in early PD stages we used MitoPark mice, a genetic model with gradual degeneration of DA cells. Daily treatment of young MitoPark mice for eight weeks with the A(2A)R antagonist MSX-3 prevented the reduction of spontaneous locomotor activity observed in saline or L-DOPA treated animals. Chronic A(2A)R antagonist treatment neither induced desensitization of receptors nor accumulation of the drug in brain tissue. Despite beneficial effects on behavior, which are not improved upon addition of a low dose of L-DOPA, the characteristic decline of dopamine levels was not changed. Our results indicate that effective dosing with A(2A)R antagonists should be tested as monotherapy in early PD, and serves to remind us that positive behavioral effects of such treatment need not be reflected in rescue of striatal dopamine levels. 2010 Elsevier Inc. All rights reserved.

引用

页码：460 / 466

页数：7

共 29 条

[1] Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].